Invention Grant
- Patent Title: Azaindazole compounds as CCR1 receptor antagonists
- Patent Title (中): 阿扎唑类化合物作为CCR1受体拮抗剂
-
Application No.: US13273509Application Date: 2011-10-14
-
Publication No.: US08163918B2Publication Date: 2012-04-24
- Inventor: Daniel Kuzmich , John Lord , Can Mao
- Applicant: Daniel Kuzmich , John Lord , Can Mao
- Applicant Address: DE Ingelheim am Rhein
- Assignee: Boehringer Ingelheim International GmbH
- Current Assignee: Boehringer Ingelheim International GmbH
- Current Assignee Address: DE Ingelheim am Rhein
- Agent Michael P. Morris; Anthony P. Bottino
- Main IPC: C07D515/04
- IPC: C07D515/04
Abstract:
Disclosed are compounds of the formula (I), useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of CCR1 including autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. Also disclosed are intermediates thereof, and methods of making and methods of using same.
Public/Granted literature
- US20120035370A1 Azaindazole Compounds As CCR1 Receptor Antagonists Public/Granted day:2012-02-09
Information query
